For the year ended 31 March, revenue rose to Y50.46 billion from Y41.72 billion, while operating profit increased to Y10.52 billion from Y8.72 billion.
Pretax profit climbed to Y9.96 billion from Y8.51 billion, but earnings per share slipped to Y103.44 from Y111.34 under IFRS reporting.
The latest filing shows stronger sales and operating performance despite lower bottom-line profit, contrasting with another Japanese healthcare company, Japan Medical Dynamic Marketing, which separately returned to annual profit.
Does this firm’s profit signal a painful but necessary economic reckoning for corporate Japan?
In Japan’s booming medical market, why is this device distributor’s revenue shrinking?